Warp Sciences Emerges From Stealth With $215M for AI-Powered Chemistry Labs

Designing a promising molecule is only the beginning of drug research. Someone still has to make it, test it, and turn the results into a better next experiment. Warp Sciences is betting that this physical bottleneck is where AI can create its next major advantage.

Warp Sciences has emerged from stealth with $215 million in funding to build a U.S.-based chemistry contract research organization, or CRO, combining experienced chemists, AI, and robotics. Led by former OpenAI Chief Product Officer Kevin Weil, the company plans to provide research compounds to biotech and pharmaceutical customers while building laboratories that learn from the experiments they perform.

Lightspeed led the financing, with participation from IVP, Mayfield, Lux, Premji Invest, and Menlo Ventures, among others. Angel investors include Brian Armstrong, Mike Krieger, Dylan Field, and OpenAI’s Mark Chen and Sarah Friar.

A Chemistry Services Business Built Around AI

Warp’s starting point is lead optimization analog synthesis: making variations of molecules so researchers can compare them as they work toward a drug candidate. It is a concrete service with a deliverable, rather than a promise that an AI model will independently invent a medicine.

According to its customer services page, Warp is focused on preclinical small-molecule programs, producing compounds at milligram to multi-gram scale. The company describes its typical work as elaborated molecules requiring five to 15 synthetic steps. That scope places it inside the repeated cycle of making and evaluating compounds that research teams need to refine a program.

Warp also makes a clear distinction about ownership of the research agenda. Customers choose which molecules to pursue and retain control of their drug programs. Warp has no proprietary drug pipeline of its own. Its business is supplying the chemistry and experimental infrastructure those teams use.

That matters commercially. A CRO has to deliver usable compounds, maintain quality, and collaborate effectively with customer scientists. Those requirements give Warp’s automation effort an immediate operational test: whether it makes the service more productive and dependable.

From Laboratory Results to Better Models

The longer-term technology thesis is a feedback loop between experimentation and machine learning. Physical experiments produce evidence about what works. AI systems learn from that evidence, help guide subsequent experiments, and support increasingly automated laboratory work. More capable labs can then produce more useful evidence.

In its founders’ manifesto, Warp says it plans to capture both successful experiments and failures. Alongside customer work, it intends to run dedicated experimental campaigns to generate data for its models. Experienced chemists will lead the laboratories as more of the workflow is automated.

Including failures is an important part of the approach. Knowing that an experiment did not produce the desired result can help define the limits of a method and inform what should be tried next. For that information to improve a model, it needs to be recorded with enough experimental context to distinguish an unproductive idea from a problem in execution.

Robotics supplies the physical side of the loop, while software connects planning, execution, and recorded outcomes. Building those systems alongside the laboratory gives Warp the opportunity to design automation around the work chemists actually perform. The proposed advantage comes from improving the entire experimental process, rather than speeding up molecular design while leaving the lab queue unchanged.

Warp’s broader ambition is scientific AI that can help scientists reason about the physical world and design informative experiments. Its announced commercial starting point remains narrower: delivering research compounds and progressively automating the work required to produce them.

Four Founders Bridging Chemistry, AI, and Operations

Kevin Weil, co-founder and CEO, most recently served as Chief Product Officer and Vice President of Science at OpenAI. His role brings experience translating advances in AI into products and operating systems around them.

Co-founder and COO DJ Patil was the first U.S. Chief Data Scientist and a founding executive at Devoted Health. Co-founder and Chief Scientific Officer Sol Reisberg previously held medicinal chemistry leadership roles at Terremoto Biosciences. Co-founder and CTO Mano Paluri was a vice president at Meta Superintelligence Labs and a founding member of FAIR.

The combination reflects the work ahead: building AI systems, running scientific operations, and delivering chemistry customers can use. Warp says its early team also includes robotics experience from Genesis, Skild AI, and 1X, alongside scientific expertise from Genentech and Lawrence Livermore National Labs.

Charging for Compounds Delivered

Warp’s pricing approach adds another dimension to the funding story. Its website says the company charges per compound delivered, with pricing agreed in consultation with the customer. If a compound is not produced, the customer does not pay for it. Warp contrasts that arrangement with CRO contracts based on full-time-equivalent staffing.

That model connects revenue to completed work. If automation reduces the effort required to make a compound reliably, Warp could improve its own economics while giving customers a more direct connection between spending and output. The company is positioning its service around domestic collaboration and control at offshore pricing, although it has not published a general price list or comparative cost results.

Warp says it is currently working with a small number of design partners. Those relationships involve weekly collaboration between customer chemists and Warp’s team, giving the startup a way to refine its service and systems against active research needs.

The Execution Challenge Behind the $215 Million

The funding gives Warp substantial backing for a business that must build physical capacity as well as software. Its opportunity is to turn chemistry services into a learning system: deliver compounds, capture experimental evidence, improve the models, and use those improvements to make subsequent work more efficient.

The announcement does not provide measured turnaround improvements, model benchmarks, or evidence that a fully autonomous laboratory is already operating. Those are distinct milestones from assembling the team and capital. The practical test will be whether Warp can repeatedly deliver the quality, speed, and economics it is promising customers.

For now, the company’s most consequential choice is where it begins. By starting with customer-led chemistry programs, Warp is tying its AI ambitions to a recurring scientific need. Each delivered compound offers a chance to earn revenue and improve the laboratory system behind the next one.